JP2015529201A5 - - Google Patents

Download PDF

Info

Publication number
JP2015529201A5
JP2015529201A5 JP2015528596A JP2015528596A JP2015529201A5 JP 2015529201 A5 JP2015529201 A5 JP 2015529201A5 JP 2015528596 A JP2015528596 A JP 2015528596A JP 2015528596 A JP2015528596 A JP 2015528596A JP 2015529201 A5 JP2015529201 A5 JP 2015529201A5
Authority
JP
Japan
Prior art keywords
olanzapine
antibody
group
sample
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015528596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529201A (ja
JP6389177B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/055817 external-priority patent/WO2014031656A1/en
Publication of JP2015529201A publication Critical patent/JP2015529201A/ja
Publication of JP2015529201A5 publication Critical patent/JP2015529201A5/ja
Application granted granted Critical
Publication of JP6389177B2 publication Critical patent/JP6389177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015528596A 2012-08-21 2013-08-20 オランザピンハプテンに対する抗体及びその使用 Active JP6389177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261691572P 2012-08-21 2012-08-21
US61/691,572 2012-08-21
PCT/US2013/055817 WO2014031656A1 (en) 2012-08-21 2013-08-20 Antibodies to olanzapine haptens and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018153217A Division JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2015529201A JP2015529201A (ja) 2015-10-05
JP2015529201A5 true JP2015529201A5 (enExample) 2016-04-28
JP6389177B2 JP6389177B2 (ja) 2018-09-12

Family

ID=50148310

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015528596A Active JP6389177B2 (ja) 2012-08-21 2013-08-20 オランザピンハプテンに対する抗体及びその使用
JP2018153217A Active JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018153217A Active JP6721641B2 (ja) 2012-08-21 2018-08-16 オランザピンハプテンに対する抗体及びその使用

Country Status (11)

Country Link
US (3) US20140057303A1 (enExample)
EP (2) EP3581195B1 (enExample)
JP (2) JP6389177B2 (enExample)
CN (2) CN104755093B (enExample)
AU (3) AU2013305895B2 (enExample)
CA (1) CA2882595C (enExample)
ES (2) ES3057437T3 (enExample)
PL (1) PL2887952T3 (enExample)
PT (1) PT2887952T (enExample)
TR (1) TR201910347T4 (enExample)
WO (1) WO2014031656A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
PL3333195T3 (pl) 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
CN105601730A (zh) * 2014-10-30 2016-05-25 北京维德维康生物技术有限公司 呋喃妥因半抗原和抗原的制备方法及其在化学发光免疫试剂盒中的应用
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN114685527B (zh) * 2020-12-25 2024-03-05 长沙博源医疗科技有限公司 一种奥氮平衍生物、免疫原、抗奥氮平特异性抗体及其制备方法与应用
CN115073492B (zh) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 一种奥氮平衍生物抗原、奥氮平抗体及其应用
CN119662553B (zh) * 2024-11-26 2025-11-28 江南大学 一种分泌奥氮平类化合物单克隆抗体的杂交瘤细胞株

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228A (en) 1849-03-27 Coejsr-shelleb
US4022780A (en) 1973-03-06 1977-05-10 Imperial Chemical Industries Limited Process for the manufacture of indole derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
WO1992013876A1 (en) * 1991-02-01 1992-08-20 Coulter Corporation METHOD OF PRODUCING F(ab')2 FRAGMENTS OF IMMUNOGLOBULINS
DE69232002T2 (de) 1991-06-07 2002-06-06 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays unter Verwendung von markierten Hapten-Analogen
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5616505A (en) * 1992-03-27 1997-04-01 Abbott Laboratories Haptens tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids
AU668159B2 (en) 1992-05-29 1996-04-26 Lilly Industries Limited Pharmaceutical compounds
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5527709A (en) 1992-06-26 1996-06-18 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays with labeled thyronine hapten analogues
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
DE69535855D1 (de) 1994-06-10 2008-11-20 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
WO1998059233A1 (en) 1997-06-23 1998-12-30 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
UA76708C2 (uk) 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
IL163666A0 (en) * 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003082877A1 (en) 2002-03-28 2003-10-09 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
US20040127489A1 (en) 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
US20040193446A1 (en) * 2003-03-27 2004-09-30 Mayer Steven Lloyd System and method for managing a patient treatment program including a prescribed drug regimen
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
PL1658277T3 (pl) * 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
WO2005028458A1 (en) 2003-09-23 2005-03-31 Fermion Oy Preparation of quetiapine
AU2004278414B2 (en) 2003-10-01 2012-05-24 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
EP1706743B1 (en) 2003-12-12 2009-11-18 Inverness Medical Switzerland GmbH Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (ja) 2004-04-26 2005-11-03 Takami Matsuyama 葉酸リセプターベータ（FR-β）に対する単クローン抗体を含有する治療薬
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
CA2699062A1 (en) 2007-09-27 2009-04-02 Novartis Ag Drug monitoring assay
US8133743B2 (en) 2007-10-19 2012-03-13 Roche Diagnostics Operations, Inc. Phenobarbital derivatives useful in immunoassay
EP3338795A1 (en) 2008-07-21 2018-06-27 Probiodrug AG Diagnostic antibody assay
AU2009279372A1 (en) * 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
AU2009305203B2 (en) 2008-10-14 2013-03-07 Entasis Therapeutics Limited Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2010096117A2 (en) * 2008-10-29 2010-08-26 Janssen Pharmaceutica Nv Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
AU2010206376B2 (en) * 2009-01-26 2012-10-18 Egalet Ltd. Controlled release formulations with continuous efficacy
EP2406288B1 (en) 2009-03-10 2016-12-14 Baylor Research Institute Antigen presenting cell targeted vaccines
US8076097B2 (en) 2009-08-19 2011-12-13 Saladax Biomedical Inc. Imatinib immunoassay
RU2595843C2 (ru) * 2009-10-16 2016-08-27 Омик Аб Способ анализа и устройства с применением магнитных частиц
CA2927380C (en) 2009-12-31 2017-07-04 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) * 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
CN102260290A (zh) 2010-05-25 2011-11-30 苏州波锐生物医药科技有限公司 喹喏啉酮类化合物及其在制备精神病药物中的用途
WO2011159537A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102276624B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法和高效液相色谱分析方法
CN102276592B (zh) 2011-06-17 2013-10-16 大连理工大学 一种奥氮平有关物质及其制备方法、分析方法
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
BR112015003393A2 (pt) 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
CA2882489A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone haptens and use thereof
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
CN110054694B (zh) 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
WO2014031645A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to risperidone haptens and use thereof
CA2882454C (en) 2012-08-21 2020-08-11 Matthew Garrett DONAHUE Haptens of olanzapine
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
EP2888263B1 (en) 2012-08-21 2018-05-09 Janssen Pharmaceutica NV Haptens of risperidone and paliperidone
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
PL3333195T3 (pl) 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
EP3305784B1 (en) 2012-08-21 2020-08-12 Janssen Pharmaceutica NV Haptens of quetiapine for use in immunoassays
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2017106508A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to quetiapine and use thereof
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
EP3588013A1 (de) 2018-06-26 2020-01-01 XelectriX Power GmbH Verfahren zur abgabe von elektrischer energie

Similar Documents

Publication Publication Date Title
JP2015529200A5 (enExample)
JP2015532646A5 (enExample)
JP2015529203A5 (enExample)
JP2015529199A5 (enExample)
Bode et al. Borna disease virus-specific circulating immune complexes, antigenemia, and free antibodies—the key marker triplet determining infection and prevailing in severe mood disorders
JP6242893B2 (ja) クエチアピンに対する抗体及びその使用
JP2015527368A5 (enExample)
JP6270845B2 (ja) アリピプラゾールに対する抗体及びその使用
CN104736561B (zh) 帕潘立酮的抗体及其用途
JP6216926B2 (ja) オランザピンに対する抗体及びその使用
JP2018503618A5 (enExample)
JP2015527365A5 (enExample)
Andrews et al. A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination
JP2015530971A5 (enExample)
JP2014509187A5 (enExample)
JP2015536446A5 (enExample)
JP2015529202A5 (enExample)
JP6949025B2 (ja) リスペリドンに対する抗体及びその使用
JP2015527367A5 (enExample)
JP2015527367A (ja) リスペリドンへの抗体及びその使用
CN111770761B (zh) H1.0k180me2抗体、其制造方法和用途
Simon et al. Validation of an Epstein-Barr virus antibody risk stratification signature for nasopharyngeal carcinoma by use of multiplex serology
JP2019504014A5 (enExample)
Aydillo et al. Transcriptome signatures preceding the induction of anti-stalk antibodies elicited after universal influenza vaccination
Lomakin et al. Two-dimensional high-throughput on-cell screening of immunoglobulins against broad antigen repertoires